Advanced Enzyme Technologies Ltd · NSE:ADVENZYMES
Advanced Enzyme Technologies — Q3 FY26 Earnings Presentation
33 slides from Advanced Enzyme Technologies's earnings presentation, Jan 31, 2026
Slide 1: Exchange filing cover letter: Earnings Presentation
/ ic/ vancecl Enzymes Whore ENZYME is Life Advanced Enzyme Technologies Ltd. CIN: L24200MH 1989PLC051018 Sun Magnetica, A wing, 5th Floor, LIC Service Road, Louiswadi, Thane ( W ) -400 604, India Tel: + 91-22-4170 3200, Fax: + 91 -22-2583 5159 Email: info@advancedenzymes.com, www.advancedenzymes.com
Slide 2: Earnings Presentation | January 2026
Advanced enzymes Where ENZYME is Life Advanced Enzyme Technologies Limited Earnings Presentation | January 2026
Slide 3: Safe Harbour Statement
Safe Harbour Statement ^ Manced enzymes Where ENZYME is Life This presentation contains forward-looking statements that reflect management’s current views with respect to certain future events and potential financial performance. Forward-looking statements are other than statements of historical fac
Slide 4: Table of Contents
^ Mancecl enzymes Where ENZYME is Life 2 Performance Summary | Q3 FY26 Business Performance PAGE: 4 PAGE: 07 4 Geographical Performance Result Summary | Q3 FY26 PAGE: 11 PAGE: 12 6 Unique Investment Case Focus Area Going Ahead PAGE: 26 PAGE: 30 TABLE OF CONTENTS Shareholders’ Information PAGE: 31 Ea
Slide 5: Results Summary - Q3 FY26 (Consolidated) Y-o-Y
Results Summary - Q 3 FY26 (Consolidated) Y-o-Y Advanced enzy 77705 >: \ IV: Revenue* (₹ mn) EBITDA (₹ mn) PAT (₹ mn) 11% 11% l l 1,691 2% 1,719 553 432 l 494 389 Q3 FY25 Q3 FY26 Q3 FY25 Q3 FY26 Q3 FY25 Q3 FY26 Revenue grew by 2% on y-o-y basis to EBITDA de-grew by 11% to ₹ 494 million in PAT increa
Slide 6: Results Summary - Q3 FY26 (Consolidated) Q-o-Q
Results Summary - Q3 FY 26 (Consolidated) Q-o-Q pnzvmpp Wherr FN7YMFn Life Revenue* (₹ mn) EBITDA (₹ mn) PAT (₹ mn) 7% 18% 3% I 1,845 601 447 432 I 1,719 I 494 Q2 FY26 Q3 FY26 Q2 FY26 Q3 FY26 Q2 FY26 Q3 FY26 Revenue de-grew by 7% on q-o-q basis to ₹ 1,719 million EBITDA de-grew by 18% to ₹ 494 milli
Slide 7: Results Summary - 9M FY26 (Consolidated) YTD
Results Summary - 9M FY 26 (Consolidated) YTD Advanced enzy 77705 >: \ IV: Revenue* (₹ mn) EBITDA (₹ mn) PAT (₹ mn) 11% 20% I l l 15% 5,424 1,488 1,658 1,284 4,697 1,072 9M FY25 9M FY26 9M FY25 9M FY26 9M FY25 9M FY26 Revenue grew by 15% on YTD basis to EBITDA grew by 11% to ₹ 1,658 million in PAT i
Slide 8: Human Nutrition
Human Nutrition ^ Manced enzymes Wherp FN7YMFn Life (₹ in (₹ in Million) Million) Q3 FY26 Q3 FY25 9M FY26 9M FY25 - 6% 962 1,018 of Sales +12% 3,396 3,022 of Sales Commentary: Commentary: 1,221 1,212 1,107 1,024 1,012 1,018 1,031 • The human nutrition segment contributed around • The human nutrition
Slide 9: Animal Nutrition
Animal Nutrition ^ Manced enzymes Wherp FN7YMFn Life (₹ in (₹ in Million) Million) Q3 FY26 Q3 FY25 9M FY26 9M FY25 241 197 of Sales +26% 694 551 of Sales Commentary: Commentary: 260 • The animal nutrition segment contributed around • The animal nutrition segment contributed around 241 14% during the
Slide 10: Industrial Bio-processing
Industrial Bio-processing ^ Manced enzymes Wherp FN7YMFn Life Q3 FY26: ₹310 mn Food (₹ in (₹ in Million) Million) 18% Q3 FY26 Q3 FY25 9M FY26 9M FY25 Q3 FY26: ₹51 mn +13% 361 321 of Sales +15% 852 740 of Sales Non-Food 3% Commentary: Commentary: 361 • The Industrial Bio-Processing segment contribute
Slide 11: Specialized Manufacturing
Specialized Manufacturing ^ Manced enzymes Wherp FN7YMFn Life (₹ in (₹ in Million) Million) Q3 FY26 Q3 FY25 9M FY26 9M FY25 +0% 155 154 of Sales +25% 482 385 of Sales Commentary: Commentary: 185 • This segment contributed about 9% during the • This segment contributed about 8% during the nine 154 15
Slide 12: Geographical performance
Geographical performance enzymes Wherp FN7YMFn Life India Americas Europe W Asia* Rest of the World 47% 29% 6% 13% 6% Q3 FY26 801 Q3 FY26 501 Q3 FY26 96 Q3 FY26 222 Q3 FY26 100 Q3 FY26 Q3 FY25 759 Q3 FY25 560 Q3 FY25 105 Q3 FY25 196 Q3 FY25 71 +6% -11% -9% +14% +40% 49% 30% 6% 12% 3% 9MFY26 2,666 9M
Slide 13: Profit & Loss (Consolidated) - Q3 FY26 & 9M FY26
Profit & Loss (Consolidated) - Q 3 FY 26 & 9 M FY 26 Advanced enzvi77705 : \ IV: (₹ in Million) Q3 FY26 Q2 FY26 Q3 FY25 Y-o-Y Q-o-Q 9M FY26 9M FY25 Y-o-Y Particulars Un-Audited Un-Audited Un-Audited (%) (%) Un-Audited Un-Audited (%) Income from Operations 1,719 1,845 1,691 2% -7% 5,424 4,697 15% Exp
Slide 14: Result summary - FY25 (Consolidated) Y-o-Y
Result summary - FY25 (Consolidated) Y-o-Y Advanced enzymes Where ENZYME Is Life (₹ in Million) Revenue* (? mn) EBITDA (? mn) PAT (? mn) 6,239 02% 6,369 2,045 05% 1,944 1,370 02% 1,340 FY24 FY25 FY24 FY25 FY24 FY25 Human HC Animal HC Bio Processing Specialized Manufacturing -03% +12% +06% +30% FY25
Slide 15: Revenue Split - FY25 vs. FY24
Revenue Split - FY 25 vs. FY 24 enzymes Wherr FN7YMFn Life 8% 7% 16% 15% Product Product Category-wise (%) Category-wise (%) 11% 12% 64% 67% Human HC Animal HC Bio-Processing Specialized Manufacturing Human HC Animal HC Bio-Processing Specialized Manufacturing 3% 3% 9% 7% 5% 6% Geographical Geograph
Slide 16: Strong Financial Performance - FY25
Strong Financial Performance - FY25 Advanced enzy 77705 > : \ IV : Revenue from Operations EBIDTA & EBIDTA Margin (%) 6,239 6,369 2,500 46% 50% L 5,294 5,406 38% 33% 31% 45% 5,018 2,000 40% 29% 35% 1,500 30% 25% 1,000 20% 15% 500 10% 2,316 2,014 1,564 2,045 1,944 5% 0 0% FY 21 FY 22 FY 23 FY 24 FY 2
Slide 17: Strong Financial Performance - FY25
Strong Financial Performance - FY25 Advanced enzymes Where ENZYME Is Life Net Working Capital (Days) Net Worth (? mn) 146 14,209 132 135 135 13,241 L 120 12,351 10,886 9,709 FY 21 FY 22 FY 23 FY 24 FY 25 FY 21 FY 22 FY 23 FY 24 FY 25 ROE (%) & ROCE (%) Net Debt to Equity (x) 21.94% 0.02 0.02 0.02 15
Slide 18: Balance Sheet (Consolidated)
Balance Sheet (Consolidated) pnzvmpp Wherp FN7YMFn Life FY25 FY24 FY23 FY22 FY21 Particulars Audited Audited Audited Audited Audited Assets Property, plant and equipment 2,929 2,765 2,732 2,622 2,462 Capital work-in-progress 217 411 215 151 102 Intangible assets 523 479 550 609 693 Goodwill 3,334 3,
Slide 19: Annexure
co) — S x< co) = S <x
Slide 20: Company Overview
Company Overview ^^ ancpcl enzymes Where ENZYME is Life Advanced Enzymes is a research driven company with global <fg> leadership in the manufacturing of enzymes and probiotics. We are committed to providing eco-safe solutions to a wide variety of industries like human health care and nutrition, ani
Slide 21: Advanced Enzyme Technologies Limited - A Rising Global Star
Advanced Enzyme Technologies Limited - A Rising Global Star Advanced enzy 77705 > : \ IV: 9 7 1st 2nd 2nd R&D Units Manufacturing Units Indian enzyme Highest market Listed integrated India – 5 | USA – 1 | India - 8USA - 1 company share in India enzyme player globally Germany –1 68+ 400+ 700+ 45+ 750
Slide 22: Brief History and Evolution
Brief History and Evolution enzymes Wherr FN7YMFn Life Incorporated as R&D locations Advanced • Equity investment • Floated IPO • 4 food enzymes got • Received NIH grant • Received approval Advanced (Thane and Sinnar) Biochemicals Ltd. is by Kotak Private • Acquired 70% stake approved as a for Immun
Slide 23: Board of Directors
Board of Directors enzymes Wherr FN7YMFn Life r T 1 Mr. Vasant Rathi Mr. Mukund Kabra Mr. Pramod Kasat Ms. Rasika Rathi Mr. Vinod Jajoo Promoter Chairman Whole-time Director Independent Director Non-Executive Director Independent Director and Non-Executive Director \ m ' 4 <7 . 'T ' . * JSEj S Q 1 \
Slide 24: Management Team
Management Team enzymes Wherr FN7YMFn Life Mr. Beni Prasad Rauka Mr. Dipak Roda Mr. Harshad Doshi Ms. Rasika Rathi Chief Financial Officer Vice President / Market CFO & COO - Advanced Enzymes, USA General Counsel / Vice President & Business Development And Secretary – Advanced Enzymes, USA Ms. Marti
Slide 25: How Big is the Opportunity?
How Big is the Opportunity? enzymes Wherr FN7YMFn Life o Global Probiotics Market Global Enzymes Market Animal Probiotics $1Bn 7% $16 Bn Grow at a CAGR Grow at a CAGR 14.12% 7.80% $4.55Bn CY 2024-29 till 2029 $8Bn $13Bn Human Probiotics $12Bn 93% $3.57Bn $3.57Bn Competitive Scenario in the Global En
Slide 26: What we are Aiming in the Opportunity?
What we are Aiming in the Opportunity? enzymes Wherr FN7YMFn Life AETL’s Current Share of Revenue Addressable market for AETL CARG(%) over next Focus Area Opportunity Size over next 5 years** 5 years FY25 FY24 Human Nutrition Pharma/API $ 80 mn $ 50 mn 6% $ 18.04 mn, 24% $ 20.32 mn, 27% Probiotics $
Slide 27: What Makes AETL a Unique Investment Case?
What Makes AETL a Unique Investment Case? Advanced enzy 77705 > : \ IV: Integrated Player Specialized Significant Focus with Presence Business with on International Across the High Entry Markets & Brand Enzyme Barriers Building Value Chain Inherent Strong Research Diversification Strong Financial &
Slide 28: Integrated Player with Presence Across the Enzyme Value Chain
Integrated Player with Presence Across the Enzyme Value Chain Advanced enzy 77705 > : \ IV: Research & Development Manufacturing Marketing & Distribution . co Earnings Presentation | January 2026 27
Slide 29: Specialized Business With High Entry Barriers
Specialized Business With High Entry Barriers enzymes Wherr FN7YMFn Life Technocrat Promoters Global Competitiveness Cumulative experience of 7+ decades Amongst the Lowest Cost Manufacturers in the in the global enzyme industry World (Benchmarked both in terms of Capex & Opex) Sustained Research & D
Slide 30: Future Growth Drivers
Future enzymes Where ENZYME is Life Growth Drivers Continued (ToOO" Broaden & Deepen Inorganic Investment in R&D Geographical Presence Expansion o Acquisition of Key Technologies, Competencies & o Identify Product gaps and Develop new Enzymes, o Increased focus on high return applications where Skil
Slide 31: Focus Areas Going Ahead
Focus enzymes • ZiU' tP ' /• Areas Going Ahead Animal Nutrition Probiotics Bio-Catalysis Baking • Continuing conduct trials and studies to bring • To introduce more probiotics products in • Developing bio catalysis for API manufacturers, • In Bio-processing division, our focus is on newer and effect
Slide 32: Shareholders Information
Shareholders Information Advanced enzymes Where ENZYME Is Life Stock Data Stock Chart 4 Market Capitalization (₹) 33,830 mn 374.15 Shares Outstanding 111.93 mn 302.25 Symbol (NSE/ BSE) ADVENZYMES / 540025 Dec-24 Jan-25 Feb-25 Mar-25 Apr-25 May-25 Jun-25 Jul-25 Aug-25 Sep-25 Oct-25 Nov-25 Dec-25 Sour
Slide 33: Thank you
Thank you Maivan Tadka ^ Advanced Enzyme Technologies Limited Address: 5th Floor, 'A' wing, Sun Magnetica LIC Service Road, Louiswadi, Thane (W) 400 604, India Tel: +91-22-4170 3200 Fax: + 91-22-25835159 Web: www.advancedenzymes.com CIN No: L24200MH1989PLC051018 9 Sun Crest rm 4 Pipe / /ne Advanced
Advanced Enzyme Technologies — Q3 FY26 Earnings Presentation on 6ix